Event Details

The Immatics team will attend and present two posters at the 41^st Annual Meeting of the Society for Immunotherapy of Cancer. 

Additionally, CEO, Harpreet Singh, and CMO, Cedrik Britten, have been invited to speak at the conference as well.

For more information, visit the conference website by clicking here.

SITC Talk Sessions

Date / Time: November 5, 2026 / 8:35-8:45 AM MT
Speaker: Cedrik Britten, MD
Pre-conference Program: New Agents in Development and Emerging Technologies
Session I: Cell Therapies and Technologies
Title: From Antigen Selection to Clinical Activity: What PRAME is Teaching us About TCR T-cell Therapy in Solid Tumors
 

Date / Time: November 5, 2026 / 11:00-11:10 AM MT
Speaker: Cedrik Britten, MD
Pre-conference Program: New Agents in Development and Emerging Technologies
Session II: Immune Cell Engagers and Bispecifics
Title: Initial Clinical Results With T-cell Receptor (TCR)-based Bispecific T-cell Engagers (TCERs) targeting PRAME and MAGEA4/8 in Advanced Solid Tumors
 

Date / Time: November 6, 2026 / 3:55-4:10 PM MT
Speaker: Harpreet Singh, PhD
Session 107b: The Next Generation of Off-the-Shelf IO
Title: Targeting PRAME with IMA402, a Novel Bispecific T-Cell Engager (TCER) – Initial Clinical Results

SITC Poster Presentations

Date: November 6, 2026
Abstract No: 275
Category: Cellular Therapies
Title: Event-driven management, risk factors, and clinical associations of cytokine release syndrome (CRS) following anzutresgene autoleucel (anzu-cel), a TCR T-cell therapy, in advanced melanoma
Presenter: Diwakar Davar, MD
 

Date: November 6, 2026
Abstract No: 313
Category: Cellular Therapies
Title: Characterization of PRAME-specific CD4-CD8+ and CD4+CD8+ T-cell populations following IMA203CD8 T-cell receptor (TCR) T-cell therapy and their associated helper and cytotoxic function
Presenter: Antonia Busse, MD